Does D-Cycloserine Enhance Exposure Therapy for Anxiety Disorders in Humans? A Meta-Analysis
Authors:
Open Access
- 1 January 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (7) , e93519
Abstract
The treatment of anxiety is on the edge of a new era of combinations of pharmacologic and psychosocial interventions. A new wave of translational research has focused on the use of pharmacological agents as psychotherapy adjuvants using neurobiological insights into the mechanism of the action of certain psychological treatments such as exposure therapy. Recently, d-cycloserine (DCS) an antibiotic used to treat tuberculosis has been applied to enhance exposure-based treatment for anxiety and has proved to be a promising, but as yet unproven intervention. The present study aimed to evaluate the efficacy of DCS in the enhancement of exposure therapy in anxiety disorders. A systematic review/meta-analysis was conducted. Electronic searches were conducted in the databases ISI-Web of Science, Pubmed and PsycINFO. We included only randomized, double-blind, placebo-controlled trials with humans, focusing on the role of DCS in enhancing the action of exposure therapy for anxiety disorders. We identified 328 references, 13 studies were included in our final sample: 4 on obsessive-compulsive disorder, 2 on panic disorder, 2 on social anxiety disorder, 2 on posttraumatic stress disorder, one on acrophobia, and 2 on snake phobia. The results of the present meta-analysis show that DCS enhances exposure therapy in the treatment of anxiety disorders (Cohen d = −0.34; CI: −0.54 to −0.14), facilitating the specific process of extinction of fear. DCS seems to be effective when administered at a time close to the exposure therapy, at low doses and a limited number of times. DCS emerges as a potential new therapeutic approach for patients with refractory anxiety disorders that are unresponsive to the conventional treatments available. When administered correctly, DCS is a promising strategy for augmentation of CBT and could reduce health care costs, drop-out rates and bring faster relief to patients.Keywords
This publication has 63 references indexed in Scilit:
- D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disordersBiology of Mood & Anxiety Disorders, 2013
- d-Cycloserine Augmentation of Behavioral Therapy for the Treatment of Anxiety DisordersThe Journal of Clinical Psychiatry, 2012
- Using cognitive enhancers to improve the treatment of anxiety disorders in young people: Examining the potential for D‐cycloserine to augment exposure for child anxietyClinical Psychologist, 2011
- A Preliminary Study of D-Cycloserine Augmentation of Cognitive-Behavioral Therapy in Pediatric Obsessive-Compulsive DisorderBiological Psychiatry, 2010
- D-Cycloserine Augmentation of Cognitive-Behavioral Therapy: Directions for Pilot Research in Pediatric Obsessive-Compulsive DisorderChild & Youth Care Forum, 2010
- Nonresponse and Dropout Rates in Outcome Studies on PTSD: Review and Methodological ConsiderationsPsychiatry, 2008
- Augmentation Treatment of Psychotherapy for Anxiety Disorders with D‐CycloserineCNS Drug Reviews, 2006
- Treatment-resistant anxiety disordersMolecular Psychiatry, 2006
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Quality of Life in Individuals With Anxiety DisordersAmerican Journal of Psychiatry, 2000